Liver transplantation: Immunosuppression and oncology

Current Opinion in Organ Transplantation

Volumn 19, Issue 3, 2014, Pages 253-260

  Rodríguez Perálvarez, Manuel ^a   De La Mata, Manuel ^a   Burroughs, Andrew K ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cancer; hepatocellular carcinoma; immunosuppression; liver transplantation; malignancy

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

CANCER RECURRENCE; CARCINOGENESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; ONCOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW;

ANTILYMPHOCYTE SERUM; AZATHIOPRINE; CALCINEURIN; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS;

EID: 84900841245     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000069     Document Type: Review

References (73)

1. Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl 2012; 18:1277-1289
2. Aberg F, Pukkala E, Hockerstedt K, et al. Risk of malignant neoplasms after liver transplantation: A population-based study. Liver Transpl2008;14:1428-1436
3. Baccarani U, Piselli P, Serraino D, et al. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis 2010; 42:55-60
4. Herrero JI, Lorenzo M, Quiroga J, et al. De Novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival. Liver Transpl 2005; 11:89-97
5. Jiang Y, Villeneuve PJ, Fenton SS, et al. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl 2008; 14:1588-1597
6. Schrem H, Kurok M, Kaltenborn A, et al. Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transpl 2013; In press.
7. Collett D, Mumford L, Banner NR, et al. Comparison of the incidence of malignancy in recipients of different types of organ: A UK Registry audit. Am J Transplant 2010; 10:1889-1896
8. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306:1891-1901
9. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: A population-based study. J Hepatol 2001; 34:84-91
10. Chatrath H, Berman K, Vuppalanchi R, et al. De novo malignancy postliver transplantation: A single center, population controlled study. Clin Transplant 2013; 27:582-590
11. Krynitz B, Edgren G, Lindelof B, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008-A Swedish population-based study. Int J Cancer 2013; 132:1429-1438
12. Oo YH, Gunson BK, Lancashire RJ, et al. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 2005; 80:759-764
13. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236
14. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57:675-688
15. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674
16. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121:1-14
17. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31:220-227
18. Shields JD, Kourtis IC, Tomei AA, et al. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010; 328:749-752
19. Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009; 125:1755-1763
20. Mbulaiteye SM, Clarke CA, Morton LM, et al. Burkitt lymphoma risk in US solid organ transplant recipients. Am J Hematol 2013; 88:245-250
21. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382:1525-1533
22. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194
23. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-Analysis. Lancet 2007; 370:59-67
24. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: A meta-Analysis. Am J Transplant 2006; 6:1578-1585
25. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76:597-602
26. Suthanthiran M, Hojo M, Maluccio M, et al. Posttransplantation malignancy: A cell autonomous mechanism with implications for therapy. Trans Am Clin Climatol Assoc 2009; 120:369-388
27. Datta D, Contreras AG, Basu A, et al. Calcineurin inhibitors activate the protooncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res 2009; 69:8902-8909
28. Tjon AS, Sint Nicolaas J, Kwekkeboom J, et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: An association with C2 monitoring and recipient age. Liver Transpl 2010; 16:837-846
29. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351:623-628
30. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11:497-503
31. Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248:857-862
32. Rodriguez-Peralvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59:1193-1199
33. Rodriguez-Peralvarez M, Germani G, Darius T, et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: A systematic review and meta-Analysis. Am J Transplant 2012; 12:2797-2814
34. Rodriguez-Peralvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol 2013; 58:262-270
35. Rodriguez-Peralvarez M,Germani G, Darius T, et al. Tacrolimus exposure after liver transplantation in randomized controlled trials: Too much for too long. Am J Transplant 2013; 13:1371-1372
36. Xu X, Ye L, Araki K. Ahmed R. mTOR, linking metabolism and immunity. Semin Immunol 2012; 24:429-435
37. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135:1972-1983; 1983 e1971-1911
38. Gaumann A, Schlitt HJ, Geissler EK. Immunosuppression and tumor development in organ transplant recipients: The emerging dualistic role of rapamycin. Transpl Int 2008; 21:207-217
39. Schumacher G, Oidtmann M, Rueggeberg A, et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005; 11:1420-1425
40. Piguet AC, Semela D, Keogh A, et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 2008; 49:78-87
41. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial. Am J Transplant 2012; 12:3008-3020
42. Watson CJ, Gimson AE, Alexander GJ, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13:1694-1702
43. Lebbe C, Euvrard S, Barrou B, et al. Sirolimus conversion for patients with posttransplant Kaposis sarcoma. Am J Transplant 2006; 6:2164-2168
44. Zhou J, Wang Z, Wu ZQ, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40:3548-3553
45. Vivarelli M, Dazzi A, Zanello M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89:227-231
46. Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14:633-638
47. Chinnakotla S, Davis GL, Vasani S, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15:1834-1842
48. Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51:1237-1243
49. Menon KV, Hakeem AR, Heaton ND. Meta-Analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 37:411-419
50. Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-Analysis. Liver Transpl 2012; 18:62-69
51. Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: An analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012; 18:1029-1036
52. Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10:190
53. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-293
54. Boudjema K, Camus C, Saliba F, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: A randomized study. Am J Transplant 2011; 11:965-976
55. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: The ReSpECT study. Am J Transplant 2009; 9:327-336
56. Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5:2954-2960
57. ONeill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: Analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:1186-1191
58. Manousou P, Cholongitas E, Samonakis D. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut 2013; In press.
59. Brem R, Karran P. Multiple forms of DNA damage caused by UVA photoactivation of DNA 6-thioguanine. Photochem Photobiol 2012; 88:5-13
60. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008; 8:24-36
61. Christenson LJ, Cherikh WS, Otley CC, et al. Allograft and overall survival of patients with posttransplant skin cancer. Dermatol Surg 2011; 37:183-191
62. Zavos G, Karidis NP, Tsourouflis G, et al. Nonmelanoma skin cancer after renal transplantation: A single-center experience in 1736 transplantations. Int J Dermatol 2011; 50:1496-1500
63. Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 2010; 32:119-130
64. Benlloch S, Berenguer M, Prieto M, et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant 2004; 4:596-604
65. Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: A meta-Analysis and meta-regression of outcomes. Transpl Int 2009; 22:892-905
66. Turner AP, Knechtle SJ. Induction immunosuppression in liver transplantation: A review. Transpl Int 2013; 26:673-683
67. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7:2619-2625
68. Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011; 17 (Suppl 3):S1-S9
69. Ramirez CB, Doria C, Frank AM, et al. Completely steroid-free immunosuppression in liver transplantation: A randomized study. Clin Transplant 2013; 27:463-471
70. Rodriguez-Peralvarez M, Manousou P, Lerut J, et al. How much immunosuppression is needed after liver transplantation? Clin Transplant 2013; In press.
71. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28:638-645
72. Starzl TE. Immunosuppressive therapy and tolerance of organ allografts. N Engl J Med 2008; 358:407-411
73. Kovarik J. From immunosuppression to immunomodulation: current principles and future strategies. Pathobiology 2013; 80:275-281